Concepedia

14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN

Fumio Suzuki, Ken Ikeda, Jouji Toyota, Yoshiyasu Karino, Takumi Ohmura, Kazuaki Chayama, Shigeru Takahashi, Yutaka Kawakami, Hiroki Ishikawa, Hideki Watanabe,

Journal of Hepatology · 2012 · 54 citations · 0 references

DOIFull text

Open access

Concepts